Presenter: Peter Greenberg, MD, Professor (Emeritus) of Medicine (Hematology)
Presenter: Michaela Liedtke, MD, Assistant Professor of Medicine (Hematology)
Presenter: Michaela Liedtke, MD
Assistant Professor of Medicine (Hematology)
Stanford University
Michaela Liedtke is an assistant professor of hematology at Stanford University. She received her medical degree from Medizinische Hochschule Hannover in Germany. View her CAP profile here.
Presenter: Frederick Hayden, MD, FACP
Professor of Medicine (Clinical Virology) and Pathology
University of Virginia
Frederick G. Hayden, MD, is Richardson Professor of Clinical Virology in the Department of Medicine at the University of Virginia School of Medicine. Dr. Hayden received his medical degree from Stanford University School of Medicine in 1973. After completing internal medicine residency and fellowship training in infectious diseases at the University of Rochester, he joined the faculty of the University of Virginia School of Medicine in 1978, initially in the Division of Epidemiology and Virology and subsequently in the Division of Infectious Diseases and International Health. His principal research interests have been influenza and rhinovirus infections with a particular focus on the development and application of antiviral agents for these and other respiratory viral diseases. He has published over 300 peer-reviewed articles, chapters and reviews and co-edited the textbook Clinical Virology, the third edition of which was recently published by ASM Press. From April 2006 to August 2008 he was a Medical Officer in the Global Influenza Program at the World Health Organization and served as liaison to the SouthEast Asia Influenza Clinical Research Network. Since September 2008 he has been working part-time on secondment from the University as influenza research coordinator at the Wellcome Trust in London.
Presenters: Mary M. Horowitz, MD, MS
Professor and Chief, Division of Hematology and Oncology
Medical College of Wisconsin
Dr. Mary Horowitz currently holds the Robert A. Uihlein, Jr. Chair in Hematologic Research and is a tenured Professor of Medicine and Chief of the Division of Hematology and Oncology at the Medical College of Wisconsin (MCW), where she is also an active blood and marrow transplant physician. She is also Chief Scientific Director of the Center for International Blood and Marrow Transplant Research. She received MCW’s Distinguished Service Award in June 2006, MCW’s highest honor. In 2010, Dr. Horowitz received the American Society of Hematology Mentor Award. The award recognizes scientists who have dedicated their life to the process of guiding, supporting and promoting the training and career development of their junior colleagues. In 2014, Dr. Horowitz received the American Society of Blood and Marrow Transplant’s Lifetime Achievement Award in recognition of her contributions to the advancement of transplantation as a therapy for life-threatening diseases.
Dr. Horowitz is a member of the editorial boards of the journals Blood, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation. She has served on the Board of Directors of the National Marrow Donor Program (NMDP) and as a member of the NMDP’s International Affairs Committee and, Research and Publications committees. Dr. Horowitz has served on the National Cancer Institute’s Cancer Clinical Investigation Review Committee, as well as on numerous advisory committees for public and private agencies, including the Data Safety and Monitoring Board of the National Heart Lung and Blood Institute’s Cord Blood Transplant Study, the Scientific Tumor Advisory Committee of the United Network for Organ Sharing, the Advisory Committee for the National Institute for Allergy and Infectious Disease Immune Tolerance Network and the 2005 Institute of Medicine Panel for Cord Blood Transplantation. She is the Principal Investigator of the Data and Coordinating Center of the U.S. Blood and Marrow Transplant Clinical Trials Network. She is also the Research and Project Director of the U.S. Stem Cell Therapeutic Outcomes Database, a component of the C.W. Bill Young Cell Transplantation Program, charged with collecting and assessing outcome data for all U.S. allogeneic transplants.
Dr. Horowitz has given more than 200 invited presentations on the subject of hematopoietic stem cell transplantation. Her research focuses on analysis of transplant outcomes with more than 250 papers in the biomedical literature.
Presenters: Nancy Berliner, MD
Chief, Division of Hematology
Harvard Medical School
Nancy Berliner served as the American Society of Hematology President in 2009. She is currently Chief of the Division of Hematology and Brigham and Women’s Hospital and a Professor of Medicine at Harvard Medical School.
Presenter: Robert Shafer, MD; Professor (Research) of Medicine (Infectious Diseases) and, by courtesy, of Pathology
Presenter: Crystal Mackall, MD
Professor of Pediatric Hematology/Oncology and Medicine Stanford University
Presenter: Ravindra Majeti MD, PhD
Pofessor of Hematology, Chief of the Division of Hematology, and Member of the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University
Ravi Majeti MD, PhD is Professor of Medicine, Chief of the Division of Hematology, and Member of the Institute for Stem Cell Biology and Regenerative Medicine at the Stanford University School of Medicine. He was an undergraduate at Harvard, earned his MD and PhD from UCSF, and trained in Internal Medicine at Brigham and Women’s Hospital in Boston. Dr. Majeti completed his Hematology Fellowship at Stanford, and is a board-certified hematologist. While at Stanford, he completed post-doctoral training in the laboratory of Irving Weissman, where he investigated acute myeloid leukemia (AML) stem cells and therapeutic targeting with anti-CD47 antibodies. With Dr. Weissman, he developed a humanized anti-CD47 antibody, initiated first-in-human clinical trials. Dr. Majeti directs an active NIH-funded laboratory that focuses on the molecular characterization and therapeutic targeting of leukemia stem cells in human hematologic disorders, particularly AML, and has published >90 peer-reviewed articles. He is a recipient of the Burroughs Wellcome Career Award for Medical Scientists, the New York Stem Cell Foundation Robertson Investigator Award, and the Leukemia and Lymphoma Society Scholar Award. Dr. Majeti is currently a member of the Committee on Scientific Affairs for the American Society of Hematology (ASH) and serves of the editorial board of Blood and eLife.
The 2021 Stanford Review of the 62nd Annual ASH Conference will highlight cutting-edge research and data on hematologic disorders presented at the webinar, as well as provide participants with updated treatment algorithms and strategies for optimizing the care of their patients. The webinar will utilize a variety of learning modalities, including case studies, panel discussions, and audience response questions, to facilitate meaningful interactions between expert faculty presenters and symposium participants. Click here to register.
Registration fee includes course materials and certificate of participation.
Registration Rate:
Physicians: $75
Nurses & Allied Health Professionals: $75
Tuition may be paid by Visa, MasterCard or check. Your email address is used for critical information, including registration confirmation, evaluation, and certificate. Be sure to include an email address that you check frequently. If you prefer to pay by phone or check, please contact the Stanford Center for CME at (650) 497-8554 for assistance.
STAP-eligible employees can use STAP funds towards the registration fees for this activity. Complete the STAP Reimbursement Request Form and submit to your department administrator.
AMA PRA Category 1 Credits™ (6.50 hours), Non-Physician Participation Credit (6.50 hours)
- Evaluate the use of new chemotherapeutics and biologics in subpopulations of acute myeloid leukemia patients based on patient clinical and genetic profiles
- To review new drug approvals and practical considerations for their safe and optimal use
- Evaluate optimal sequencing and combinations of novel agents for CLL and lymphomas
- To use case-based discussions to evaluate the role of new therapies in non-malignant hematology indications
- Incorporate available therapeutic options for patients with low- or high-risk myelodysplastic syndromes and utilize the revised international prognostic scoring system (IPSS-R) with new mutation data to classify patients for treatment
The Stanford University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The Stanford University School of Medicine designates this Live Activity for a maximum of 6.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The California Board of Registered Nursing recognizes that Continuing Medical Education (CME) is acceptable for meeting RN continuing education requirements as long as the course is certified for AMA PRA Category 1 CreditsTM (rn.ca.gov). Nurses will receive a Certificate of Participation following this activity that may be used for license renewal.
Cancellation Policy
Cancellations received in writing no less than 20 days before the course will be refunded, less a 20% administrative fee. No refunds will be made on cancellations received after that date. Please send cancellation requests to stanfordcme@stanford.edu.
Stanford University School of Medicine reserves the right to cancel or postpone this program if necessary; in the event of cancellation, course fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.
Accessibility Statement
Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.
Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws. You are encouraged to visit the Multicultural Health Portal: http://lane.stanford.edu/portals/cultural.html
For activity related questions, please contact
Name: Mary Sisney
Title: Marketing & Meeting Planning Specialist
Ph: (530) 680-0695
Email: msisney@stanford.edu
For CME general questions, please contact
Ph: (650)-497-8554
Email: stanfordcme@stanford.edu